Porton Pharma Solutions (SZSE:300363) Long-Term Capital Lease Obligation : ¥613 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions Long-Term Capital Lease Obligation?

Porton Pharma Solutions's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥613 Mil.

Porton Pharma Solutions's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (¥393 Mil) to Dec. 2023 (¥621 Mil) but then declined from Dec. 2023 (¥621 Mil) to Mar. 2024 (¥613 Mil).

Porton Pharma Solutions's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥207 Mil) to Dec. 2022 (¥207 Mil) but then increased from Dec. 2022 (¥207 Mil) to Dec. 2023 (¥621 Mil).

Porton Pharma Solutions Long-Term Capital Lease Obligation Historical Data

The historical data trend for Porton Pharma Solutions's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Porton Pharma Solutions Long-Term Capital Lease Obligation Chart

Porton Pharma Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

82.15

207.34

207.33

621.38

Porton Pharma Solutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															375.20	366.90	393.23	621.38	612.71

Porton Pharma Solutions (SZSE:300363) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Porton Pharma Solutions Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Porton Pharma Solutions (SZSE:300363) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714

Website

http://www.porton.cn

Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.

Executives

Wang Zhong Neng	Executives
Yu Yong Mei	Executives
Sun Min	Executives
Ji Yao Hui	Executives
Ju Nian Feng	Directors, executives
Tan Jun	Supervisors
Xu Ai Wu	Directors, executives
Guo Yong Qing	Independent director
	Director
	Director
Ceng Hui	Supervisors
Chen Bei	Executives

Porton Pharma Solutions (SZSE:300363) Headlines

No Headlines